News / Korea / yonhap_finance
Shinhan Securities Advises Cautious Stance on Aesthetic Medical Device Stocks Ahead of Q3 Results
Health Technology · Medical Specialties · yonhap_finance · 2026-09-10
145020, 214450
Shinhan Securities recommends a conservative investment approach for aesthetic medical device stocks until Q3 earnings provide clearer market signals.
What Happened
Market Outlook: Shinhan Securities maintains an 'Overweight' rating on the aesthetic medical device sector, citing long-term growth potential, while advising a cautious approach until macroeconomic uncertainties subside and Q3 earnings are confirmed. Recent stock weakness is attributed to geopolitical risks and concerns over rising interest rates, which have dampened investor sentiment.
Company Analysis: Analysts highlighted that the fundamentals of key players remain intact, with PharmaResearch continuing high growth through channel expansion and Hugel entering a core growth phase following its U.S. direct sales launch. PharmaResearch was named the top pick, while Hugel was identified as a preferred stock.
Demand Trends: The rise of GLP-1 weight-loss drugs is creating secondary demand for aesthetic procedures to address facial volume loss and skin sagging. This trend suggests a significant expansion in the total addressable market for aesthetic treatments, providing a strong tailwind for Korean companies.
Strategic Investment: Increased interest from global players, such as Eli Lilly's venture capital arm exploring investments in the Korean aesthetic sector, underscores the industry's competitiveness. Investors are encouraged to focus on companies with clear visibility and growth prospects amidst the current volatile macroeconomic environment.